Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) US biologics subsidiary MedImmune has in-licensed tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody, from global behemoth Pfizer (NYSE: PFE).
Under the terms of this accord, MedImmune will assume global development rights to tremelimumab and Pfizer will retain the rights to use tremelimumab with specified types of combination therapies. MedImmune plans to explore tremelimumab in a number of potential cancer indications.
Financial terms of the agreement – which is contingent on expiration or termination of the waiting period under the Hart Scott-Rodino Antitrust Improvements Act - were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze